Trial Profile
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2022
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary)
- Indications Crohn's disease; Rectal fistula
- Focus Proof of concept; Therapeutic Use
- Acronyms Divergence2
- Sponsors Gilead Sciences
- 11 Oct 2022 Results of radiologic evaluation of Filgotinib treatment in perianal fistulizing Crohns Disease using a The Perianal Fistula Activity Index (PFAI), presented at the 30th United European Gastroenterology Week
- 17 Mar 2021 Status changed from active, no longer recruiting to completed.
- 17 Mar 2021 This trial has been completed in Czech Republic (Global End Date: 17 Feb 2021).